Tissue roll scaffolds

ABSTRACT

An apparatus and system for treating a wound having a cavity is disclosed. The apparatus comprises a scaffold including a scaffold lamina and a tissue lamina wherein the scaffold lamina forms a laminate in fluid communication with the tissue lamina. The laminate is rolled into a generally cylindrical shape having two end surfaces. The apparatus further comprises a manifold having a port for coupling to a source of reduced pressure and that is positioned in fluid communication with the scaffold to provide reduced pressure to the scaffold lamina and the wound. The apparatus also comprises a drape formed of substantially impermeable material to cover the scaffold and the manifold within the wound. A method for treating a wound having a cavity is also disclosed and comprises positioning a scaffold lamina adjacent a tissue lamina to form a laminate in fluid communication with the tissue lamina, rolling the laminate into a generally cylindrical shape having two end surface, and positioning the scaffold within the cavity of the wound to provide reduced pressure to the wound. The method further comprises positioning a manifold in fluid communication with the scaffold to provide reduced pressure to the scaffold lamina and the wound.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Divisional of U.S. patent application Ser. No.12/648,475, filed on Dec. 29, 2009 which claims priority to U.S.Provisional Application Nos. 61/142,053 and 61/142,065, each filed onDec. 31, 2008. This application also claims priority to U.S. ProvisionalApplication No. 61/234,692, filed on Aug. 18, 2009 and U.S. ProvisionalApplication No. 61/238,770, filed on Sep. 1, 2009. Each of the foregoingapplications is incorporated herein by reference in their entirety.

BACKGROUND

1. Field of the Invention

The present application relates generally to tissue engineering and inparticular to apparatuses and systems suitable for use as scaffolds inthe treatment of wounds.

2. Description of Related Art

Clinical studies and practice have shown that providing a reducedpressure in proximity to a tissue site augments and accelerates thegrowth of new tissue at the tissue site. The applications of thisphenomenon are numerous, but application of reduced pressure has beenparticularly successful in treating wounds. This treatment (frequentlyreferred to in the medical community as “negative pressure woundtherapy,” “reduced pressure therapy,” or “vacuum therapy”) provides anumber of benefits, including faster healing and increased formation ofgranulation tissue. Typically, reduced pressure has been applied totissue through a porous pad or other manifolding device. The porous padcontains pores that are capable of distributing reduced pressure to thetissue and channeling fluids that are drawn from the tissue. The porouspad often is incorporated into a dressing having other components thatfacilitate treatment. A scaffold can also be placed into a defect tosupport tissue growth into the defect. The scaffold is usuallybioabsorbable, leaving new tissue in its place.

Scaffolds for reduced pressure treatment are described in, e.g.,WO08/091521, WO07/092397, WO07/196590, WO07/106594. The adequacy ofcurrent scaffolds can be evaluated in light of knowledge of woundhealing. Injury to body tissues results in a wound healing response withsequential stages of healing that include hemostasis (seconds to hours),inflammation (hours to days), repair (days to weeks), and remodeling(weeks to months). A high level of homology exists across most tissuetypes with regards to the early phases of the wound healing process.However, the stages of healing for various tissues begin to diverge astime passes, with involvement of different types of growth factors,cytokines, and cells. The later stages of the wound healing response aredependent upon the previous stages, with increasing complexity in thetemporal patterning of and interrelationships between each component ofthe response.

Strategies to facilitate normal repair, regeneration, and restoration offunction for damaged tissues have focused on methods to support andaugment particular steps within this healing response, especially thelatter aspects of it. To this end, growth factors, cytokines,extracellular matrix (ECM) analogs, exogenous cells and variousscaffolding technologies have been applied alone or in combination withone another. Although some level of success has been achieved using thisapproach, several key challenges remain. One main challenge is that thetiming and coordinated influence of each cytokine and growth factorwithin the wound healing response complicate the ability to addindividual exogenous factors at the proper time and in the correctcoordination pattern. The introduction of exogenous cells also facesadditional complications due to their potential immunogenicity as wellas difficulties in maintaining cell viability.

Synthetic and biologic scaffolds have been utilized to providethree-dimensional frameworks for augmenting endogenous cell attachment,migration, and colonization. To date nearly all scaffolds have beendesigned with the idea that they can be made to work with the biology.Traditional scaffolding technologies, however, rely on the passiveinflux of endogenous proteins, cytokines, growth factors, and cells intothe interstitium of the porous scaffold. As such, the colonization ofendogenous cells into the scaffold is limited by the distance away fromvascular elements, which provide nutrient support within a diffusionlimit of the scaffold, regardless of tissue type. In addition, thescaffolds can also elicit an immunogenic or foreign body response thatleads to an elongated repair process and formation of a fibrous capsulearound the implant. Taken together, these complications can all lead toless than functional tissue regeneration at the implantation or injurysite.

It would therefore be advantageous to provide additional systems for therepair and remodeling of specialized tissues. The present inventionprovides such systems.

SUMMARY

The systems, apparatuses, and methods of the illustrative embodimentsdescribed herein provide active guidance of tissue repair andregeneration through an implanted scaffold and manifold. In oneembodiment, an apparatus for treating a wound having a cavity isdisclosed. The apparatus comprises a scaffold including a scaffoldlamina and a tissue lamina wherein the scaffold lamina has edges andforms a laminate in fluid communication with the tissue lamina. Thelaminate is rolled into a generally cylindrical shape having two endsurfaces. The rolled scaffold is positioned within the cavity of thewound and provides reduced pressure to the wound. The apparatus furthercomprises a manifold having a port for coupling to a source of reducedpressure that is positioned in fluid communication with the scaffold toprovide reduced pressure to the scaffold lamina and the wound. Theapparatus may also comprise a drape formed of substantially impermeablematerial to cover the scaffold and the manifold within the wound tosubstantially maintain the reduced pressure within the wound whenprovided by the manifold. Reduced pressure may likewise be maintainedwithin the wound by closure of the soft tissues and skin over the woundor application site.

In another embodiment, a method for treating a wound having a cavity isalso disclosed and comprises positioning a scaffold lamina adjacent atissue lamina to form a laminate in fluid communication with the tissuelamina, rolling the laminate into a generally cylindrical shape havingtwo end surfaces, and positioning the scaffold within the cavity of thewound to provide reduced pressure to the wound. The method furthercomprises positioning a manifold in fluid communication with thescaffold to provide reduced pressure to the scaffold lamina and thewound, and then covering the scaffold and the manifold within the woundwith a substantially impermeable material to maintain the reducedpressure within the wound when provided by the manifold. Reducedpressure may likewise be maintained within the wound by closure of thesoft tissues and skin over the wound or application site.

Other objects, features, and advantages of the illustrative embodimentswill become apparent with reference to the drawings and detaileddescription that follow.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a schematic cross-section of a first illustrative embodimentof a system for treating a surface wound on a patient including acomposite scaffold and a side-mounted manifold;

FIG. 1B is a cross-section of the composite scaffold taken on the line1B-1B in FIG. 1A;

FIG. 2 is a schematic cross-section of a second illustrative embodimentof a system for treating a subcutaneous wound on a patient including acomposite scaffold and a side-mounted manifold;

FIG. 3 is a schematic, perspective view, of the composite scaffold andthe side-mounted manifold of FIGS. 1 and 2;

FIG. 4 is a schematic cross-section of a third illustrative embodimentof a system for treating a surface wound on a patient including acomposite scaffold and an end-mounted manifold;

FIG. 5 is a schematic cross-section of a fourth illustrative embodimentof a system for treating a subcutaneous would on a patient including acomposite scaffold and an end-mounted manifold;

FIG. 6 is a schematic, perspective view, of the composite scaffold andthe end-mounted manifold of FIGS. 4 and 5; and

FIG. 7 is a schematic view of a fluid control system for the systemshown in FIGS. 1A and 4.

DETAILED DESCRIPTION

In the following detailed description of the illustrative embodiments,reference is made to the accompanying drawings that form a part hereof.These embodiments are described in sufficient detail to enable thoseskilled in the art to practice the invention, and it is understood thatother embodiments may be utilized and that logical structural,mechanical, electrical, and chemical changes may be made withoutdeparting from the spirit or scope of the invention. To avoid detail notnecessary to enable those skilled in the art to practice the embodimentsdescribed herein, the description may omit certain information known tothose skilled in the art, The following detailed description is,therefore, not to be taken in a limiting sense, and the scope of theillustrative embodiments are defined only by the appended claims.

The term “reduced pressure” as used herein generally refers to apressure less than the ambient pressure at a tissue site that is beingsubjected to treatment. In most cases, this reduced pressure will beless than the atmospheric pressure at which the patient is located.Alternatively, the reduced pressure may be less than a hydrostaticpressure associated with tissue at the tissue site. Although the terms“vacuum” and “negative pressure” may be used to describe the pressureapplied to the tissue site, the actual pressure applied to the tissuesite may be significantly more than the pressure normally associatedwith a complete vacuum. Reduced pressure may initially generate fluidflow in the area of the tissue site. As the hydrostatic pressure aroundthe tissue site approaches the desired reduced pressure, the flow maysubside, and the reduced pressure is then maintained. Unless otherwiseindicated, values of pressure stated herein are gauge pressures.Similarly, references to increases in reduced pressure typically referto a decrease in absolute pressure, while decreases in reduced pressuretypically refer to an increase in absolute pressure.

Referring to FIGS. 1A and 1B, a first illustrative embodiment of areduced-pressure system 100 for applying reduced pressure at a tissuesite in the body of a patient to repair a defect. As used herein theterm “defect” refers to a tissue site in need of tissue repair orbulking. For example, the defect may be a wound such as a laceration, anincision, a burn or an ulcer. A defect may also be an induced defectsuch as an incision or puncture made by a surgeon in otherwise healthytissue for the purposes of bulking the tissue (e.g., such as in cosmeticsurgery). Examples of tissue sites that may be bulked by implantation ofan apparatus according to the invention include, but are not limited to,the breasts, buttocks, neck and face (e.g., the lips, chin or cheeks).For example, FIG. 1A shows a surface wound 102 having an opening in theepidermis 104 extending into the dermis 106 and forming a cavity. Thesurface wound may extend to different depths including into thesubcutaneous tissue (not shown) below the dermis 106. Referring to FIG.2, a reduced-pressure system 200 is shown with another example of awound. The wound in FIG. 2 is a subcutaneous wound 202 having anincisional opening in the epidermis 104 extending through the dermis 106into a cavity within the subcutaneous tissue 208. The reduced-pressuresystem 200 is otherwise substantially similar to the reduced-pressuresystem of FIG. 1 and, as such, utilizes the same reference numerals usedin FIG. 1 for the same components.

Referring back to FIG. 1 with reference to FIG. 2 as well, thereduced-pressure system 100 comprises a dressing assembly 110 positionedover the surface wound 102 and a reduced-pressure source 112 forproviding a reduced pressure to the dressing assembly 110. The system100 further comprises a canister 114 having a filter (not shown)contained within the canister 114 that is coupled in fluid communicationwith the reduced-pressure source 112 via a conduit 116. The canister 114is also in fluid communication with the reduced pressure dressing 110via a second conduit 118 and a conduit connector 119. The canister 114may be a fluid reservoir, or collection member, to filter or holdexudates and other fluids removed from the surface wound 102. In oneembodiment, the canister 114 and the reduced-pressure source 112 areintegrated into a single housing structure.

As used herein, the term “coupled” includes direct coupling or indirectcoupling via separate object. The term “coupled” also encompasses two ormore components that are continuous with one another by virtue of eachof the components being formed from the same piece of material. Also,the term “coupled” may include chemical, mechanical, thermal, orelectrical coupling. Fluid coupling means that fluid is in communicationwith the designated parts or locations.

The dressing assembly 110 further comprises a distribution manifold 120adapted to be positioned at the opening of the surface wound 102, and adrape 122 adapted to cover the distribution manifold 120 to maintainreduced pressure beneath the drape 122 within the cavity of surfacewound 102. The drape 122 includes an aperture 124 through which theconduit connector 119 extends to provide fluid communication between thesecond conduit 118 and the distribution manifold 120. The drape 122 alsoincludes a periphery portion 126 that extends beyond the perimeter ofthe opening of the surface wound 102 that includes an adhesive orbonding agent (not shown) to secure the drape 122 to the healthy tissueadjacent the opening of the surface wound 102. In one embodiment, theadhesive disposed on the drape 122 may be used to provide a seal betweenthe epidermis 104 and the drape 122 to maintain reduced pressure withinthe surface wound 102. In another embodiment, a seal layer (not shown)such as, for example, a hydrogel or other material, may be disposedbetween the drape 122 and the epidermis 104 to augment or substitute forthe sealing properties of the adhesive.

The drape 122 may be any material that provides a pneumatic or fluidseal. The drape 122 may, for example, be an impermeable orsemi-permeable, elastomeric material. “Elastomeric” means having theproperties of an elastomer, and generally refers to a polymeric materialthat has rubber-like properties. More specifically, most elastomers haveelongation rates greater than 100% and a significant amount ofresilience. The resilience of a material refers to the material'sability to recover from an elastic deformation. Examples of elastomersmay include, but are not limited to, natural rubbers, polyisoprene,styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrilerubber, butyl rubber, ethylene propylene rubber, ethylene propylenediene monomer, chlorosulfonated polyethylene, polysulfide rubber,polyurethane, EVA film, co-polyester, and silicones. Specific examplesof drape materials include a silicone drape, 3M Tegaderm® drape, V.A.C.™Drape™, acrylic drape such as one available from Avery Dennison, or anincise drape.

The dressing assembly 110 further comprises a composite scaffold 130positioned within the cavity of surface wound 102 in fluid communicationwith the manifold 120 for applying reduced pressure to the cavity of thesurface wound 102 and to provide a structure for promoting the growth oftissue within the cavity of the surface wound 102. The compositescaffold 130 may be partially or fully in contact with the cavity wallsof the surface wound 102 being treated. When the composite scaffold 130is in contact with the walls of the surface wound 102, the compositescaffold 130 may partially or fully fill the void of the surface wound102. The composite scaffold 130 may be any size, shape, or thicknessdepending on a variety of factors, such as the type of treatment beingimplemented or the nature and size of the cavity of the surface wound102.

In one illustrative embodiment, the distribution manifold 120 is a foammaterial that distributes reduced pressure to the composite scaffold 130and the cavity of the surface wound 102 when the distribution manifold120 is in contact with or near the composite scaffold 130. The foammaterial may be either hydrophobic or hydrophilic. In one non-limitingexample, the distribution manifold 120 is an open-cell, reticulatedpolyurethane foam such as GranuFoam® dressing available from KineticConcepts, Inc. of San Antonio, Tex. In the example in which thedistribution manifold 120 is made from a hydrophilic material, thedistribution manifold 120 also functions to wick fluid away from thecomposite scaffold 130 and the cavity of the surface wound 102, whilecontinuing to provide reduced pressure to the composite scaffold 130 asa manifold. The wicking properties of the distribution manifold 120 drawfluid away from the cavity of the surface wound 102 by capillary flow orother wicking mechanisms. An example of a hydrophilic foam is apolyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam® dressingavailable from Kinetic Concepts, Inc. of San Antonio, Tex. Otherhydrophilic foams may include those made from polyether. Other foamsthat may exhibit hydrophilic characteristics include hydrophobic foamsthat have been treated or coated to provide hydrophilicity.

Referring to FIG. 2, the reduced-pressure system 200 further comprises aflange portion 219 of the conduit connector 119 positioned between thedrape 122 and the epidermis 104 and a third conduit 218 supported by theflange portion 219 and extending therefrom into the cavity of thesubcutaneous wound 202. The reduced-pressure system 200 furthercomprises a distribution manifold 220 fluidly coupled to the conduitconnector 119 via the third conduit 218. The distribution manifold 220is substantially similar to the distribution manifold 120 (FIG. 1), butis constructed from bioresorbable materials that do not have to beremoved from a patient's body following use of the dressing assembly210. Suitable bioresorbable materials may include, without limitation, apolymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA).The polymeric blend may also include, without limitation,polycarbonates, polyfumarates, and capralactones. The distributionmanifold 220 may further serve as a scaffold for new cell-growth, or ascaffold material may be used in conjunction with the distributionmanifold 220 to promote cell-growth. A scaffold is a substance orstructure used to enhance or promote the growth of cells or formation oftissue, such as a three-dimensional porous structure that provides atemplate for cell growth. Illustrative examples of scaffold materialsinclude calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites,carbonates, or processed allograft materials.

Referring to FIG. 3, the composite scaffold 130 comprises a strip oftissue such as, for example, adipose tissue sandwiched together with astrip of scaffold material, i.e., a tissue lamina 134 and a scaffoldlamina 132, respectively, forming a laminate 136. The laminate 136 maythen be rolled into a generally cylindrical shape as shown with one endportion rolled inside the composite scaffold 130, i.e., the internal endportion 138, and the other end portion rolled outside the compositescaffold 130, i.e., the external end portion 137. The surfaces of thescaffold lamina 132 are in fluid communication with the surfaces of thetissue lamina 134. In one embodiment, the scaffold lamina 132 isrelatively thin and best suited for maintaining the viability of thetissue lamina 134 before and after being transferred to the cavities ofthe wounds 102, 202. In another embodiment, the scaffold lamina 132 isrelatively thicker so that it not only maintains the viability of thetissue lamina 134, but also expands the tissue lamina 134 as the tissuelamina 134 grows into the scaffold lamina 132 increasing in volume andbulk while in the cavities of the wounds 102, 202. It should beunderstood that the composite scaffold 130 or laminate 136 may betreated in vitro with fluids or the application reduced pressure priorto being transferred to the patient and/or in vivo with native fluidsfrom the cavities of the wounds 102, 202 or with other fluids asdescribed below in conjunction with the system shown in FIG. 7.

When the composite scaffold 130 is positioned in the cavity of thesurface wound 102 as described above, the manifold 120 is in fluidcommunication with the edges of the scaffold lamina 132 as describedabove and shown by arrows 139 in FIGS. 1A and 3. The scaffold lamina 132is preferably bioabsorbable and as such will be absorbed as the tissuein the cavity of the surface wound 102 and the tissue lamina 134 growsin vivo to fill the cavity. As indicated above, the composite scaffold130 may be rolled into any size and shape to fill or partially the fillthe cavity of the surface wound 102 and the subcutaneous wound 202.

The tissue lamina 134 according to the invention may be any type oftissue desired for implantation, such as adipose tissue. In certainembodiments, the tissue of the tissue lamina 134 is the same type oftissue that surrounds a defect (e.g., wound) site. The tissue lamina 134may be allograft, autograft, xenograft tissue or may be a tissuegenerated in vitro from a population of pluripotent cells. In certainaspects, the tissue lamina 134 comprises a substantially intact slice oftissue that is shaped to fit a scaffold lamina 132. In certain otheraspects, the tissue lamina 134 may be composed of raw lipoaspirate orcells separated from the lipoaspirate.

The fluid communication between the manifold lamina 132 and the tissuelamina 134 composed of adipose tissue allows the cells in the adiposetissue to remain viable while the introduced tissue undergoesneovascularization (or revascularization in the case of graft tissue).In particular, fluid flow through the tissue removes metabolic wasteproducts from the tissue and draws nutrients such as oxygen from thesurrounding tissue into the introduced tissue. Thus, fluid flow not onlymaintains the viability of cells in the tissue lamina 134, but alsopromotes proliferation of the cells and bulking a tissue defect such asthe surface wound 102.

Referring to FIG. 4, a third illustrative embodiment of areduced-pressure system 300 for applying reduced pressure at a tissuesite in the body of a patient to repair the surface wound 102 is shownand comprises the same components as the reduced-pressure system 100 inFIG. 1 as indicated by the reference numbers. Referring to FIG. 5, afourth reduced-pressure system 400 for applying reduced pressure to thesubcutaneous wound 202 is shown and comprises the same components as thereduced-pressure system 200 in FIG. 2 as indicated by the referencenumbers. The reduced-pressure systems 300 and 400 are substantially thesame as the systems 100 and 200, respectively, other than the manifoldsand composite scaffolds. The reduced-pressure systems 300, 400 comprisea dressing assembly 310 and 410, respectively, each one of whichincludes a distribution manifold 320 and a composite scaffold 330.

The composite scaffold 330 also comprises a scaffold lamina 332 and atissue lamina 334 that form a laminate 336 which also may be rolled intoa generally cylindrical shape as shown in FIG. 6. The rolled laminate336 also has an external end portion 337 and an internal end portion 338within the composite scaffold 330. In this embodiment, however, thedistribution manifold 320 is fluidly coupled to the scaffold lamina 332at the external end portion 337 of the composite scaffold 330 ratherthan at the edges of the scaffold lamina 332. The scaffold lamina 332has sufficient porosity to fluidly communicate the reduced pressure tosubstantially the full length of the tissue lamina 334. The scaffoldlamina 332 may have a porosity that increases toward the inside of thecomposite scaffold 330 to create a reduced-pressure gradient within thecomposite scaffold 330. Otherwise, the scaffold lamina 332 issubstantially similar to the scaffold lamina 132. When the compositescaffold 330 is positioned in either type of wound 102, 202, themanifold 320 is fluidly coupled to the third conduit 218 fordistributing reduced pressure to the composite scaffold 330 as describedabove. In this embodiment, however, the composite scaffold 330 isoriented within the cavities of the wounds 102, 202 such that thelongitudinal axis of the composite scaffold 330 is aligned generallyparallel with the epidermis 104 rather than perpendicular. The structureand orientation of this distribution manifold 320 and composite scaffold330 may be better suited for different types of wounds such as, forexample, a surface or subcutaneous wound with an incisional cut throughthe epidermis 104 and the dermis 106.

Referring to FIG. 7, the reduced pressure therapy systems 100, 200, 300,and 400 (collectively, the “systems”) may further comprise a pressuresensor 140 operably connected to the second conduit 118 to measure thereduced pressure being applied to the manifolds 120, 220, 320, and 420(collectively, the “manifolds”). The systems further include a controlunit 145 electrically connected to the pressure sensor 140 and thereduced pressure source 112. The pressure sensor 140 measures thereduced pressure within the cavity of the wounds 102, 202 (collectively,the “wounds”) and also may indicate whether the second conduit 118 isoccluded with blood or other bodily fluids. The pressure sensor 140 alsoprovides feedback to control unit 145 which regulates the reducedpressure therapy being applied by the reduced pressure source 112through the second conduit 118 to the manifolds. The reduced pressuretherapy systems may also comprise a fluid supply 150 fluidly coupled tothe second conduit 118 via a fourth conduit 152 and operativelyconnected to the control unit 145. The fluid supply 150 may be used todeliver growth and/or healing agents to the scaffolds 130 and 330(collectively, the “scaffolds”) for the wounds including, withoutlimitation, an antibacterial agent, an antiviral agent, a cell-growthpromotion agent, an irrigation fluid, or other chemically active agents.The systems further comprise a first valve 154 positioned in the fourthconduit 152 to control the flow of fluid therethrough, and a secondvalve 156 positioned in the second conduit 118 between the reducedpressure supply 112 and the juncture between the second conduit 118 andthe fourth conduit 152 to control the flow of reduced pressure. Thecontrol unit 145 is operatively connected to the first and second valves154, 156 to control the delivery of reduced pressure and/or fluid fromthe fluid supply 150, respectively, to the manifolds as required by theparticular therapy being administered to the patient. The fluid supply150 may deliver the liquids as indicated above, but may also deliver airto the manifolds to promote healing and facilitate drainage at the siteof the wounds.

In the embodiment illustrated in FIG. 7, the reduced-pressure source 112is an electrically-driven vacuum pump. In another implementation, thereduced-pressure source 112 may instead be a manually-actuated ormanually-charged pump that does not require electrical power. Thereduced-pressure source 112 instead may be any other type of reducedpressure pump, or alternatively a wall suction port such as thoseavailable in hospitals and other medical facilities. Thereduced-pressure source 112 may be housed within or used in conjunctionwith a reduced pressure treatment unit (not shown), which may alsocontain sensors, processing units, alarm indicators, memory, databases,software, display unites, and user interfaces that further facilitatethe application of reduced pressure treatment to the wounds. In oneexample, a sensor or switch (not shown) may be disposed at or near thereduced-pressure source 112 to determine a source pressure generated bythe reduced-pressure source 112. The sensor may communicate with thecontrol unit 145 that monitors and controls the reduced pressure that isdelivered by the reduced-pressure source 112.

As used herein, the term “manifold” refers to a substance or structurethat is provided to assist in directing reduced pressure to, deliveringfluids to, or removing fluids from a tissue site. A manifold can includea plurality of flow channels or pathways that are interconnected toimprove distribution of fluids provided to and removed from the area oftissue around the manifold. Examples of manifolds may include, withoutlimitation, devices that have structural elements arranged to form flowchannels, cellular foams such as open-cell foam, porous tissuecollections, and liquids, gels and foams that include or cure to includeflow channels. A detailed description of manifolds and their useaccording to the invention is provided below.

The term “scaffold” as used herein refers to a substance or structureapplied to or in a wound or defect that provides a structural matrix forthe growth of cells and/or the formation of tissue. A scaffold is oftena three dimensional porous structure. The scaffold can be infused with,coated with, or comprised of cells, growth factors, extracellular matrixcomponents, nutrients, integrins, or other substances to promote cellgrowth. A scaffold can take on characteristics of a manifold bydirecting flow through the matrix. A manifold can transmit flow to thescaffold and tissue; in the context of reduced pressure treatment, themanifold can be in fluid communication with the scaffold. A detaileddescription of scaffolds and their use according to the invention isprovided below.

As such, the invention disclosed here discloses methods and apparatusesfor controlling cellular-level based patterns of fluid flow that wouldallow for control of patterned protein organization at a microscopic,nanoscopic, or mesoscopic scale amenable to provide a structuredmanifold and, optionally, a scaffold material for cellular migration,differentiation, and like behavior necessary for functional regenerationof tissues. In comparison to the passive nature of the current state ofthe art with regards to tissue repair and regeneration, the methods,scaffolds, manifolds, flow sources and systems disclosed herein providean active mechanism by which to promote the endogenous deposition ofproteins and organization of the provisional matrix with biochemical andphysical cues to direct cellular colonization of a scaffold or tissuespace. The present invention thus enhances current technology byexploiting the active force of directed fluid flow, providing aframework upon which to design manifolds and scaffolds based upon theneed of the biology under the influence of fluid flow. Flow vectors andpathways are utilized to enhance protein deposition and cellularcolonization. The systems provided herein are designed to promoteestablishment of a provisional matrix network with a seamless transitionfrom the healthy tissue edges through a scaffold or tissue site topromote a functional tissue continuum.

Thus, the apparatuses, methods and systems disclosed herein provide ameans for active guidance of tissue regeneration through an implantedscaffold or within a tissue site to promote functional recovery. Thisactive guidance occurs through mechanisms of controlled fluid flow,which can be used to initiate or augment the early stages of the body'sown natural healing process; a manifold can provide the active guidancenecessary to create a controlled fluid flow. Specifically, thecontrolled flow vectors that the manifolds provide can be used tofacilitate the directed influx of cells and proteins into a scaffold.Creation of specific flow pathways within a tissue site or scaffold canlead to patterned deposition of proteins, such as collagen and fibrinwithin the manifold, scaffold or tissue space. Biochemical cues fromcytokines, growth factors, and cells bound within the provisional matrixcan work in conjunction with the natural physical cues of theprovisional matrix and extracellular matrix to guide the subsequentmigration of endogenous cells during the repair stages of healing. Thesecues act as a form of track that emanates from the healthy tissues andpasses through the scaffolding or tissue space to facilitate acontinuous guidance pathway for organized tissue regeneration.

To that end, this disclosure provides unique manifolding technologiesdesigned for specific biological needs based upon principles of fluidflow. In certain aspects, the invention concerns a new approach to woundhealing, flow (or gradient) activated tissue engineering. In rudimentaryform, this approach involves a source or generator of flow that forms agradient for controlled movement of either endogenous or exogenousfluids into, out of, or through a tissue space for the organizeddeposition of proteins and/or spatial concentration of cytokines andgrowth factors, with subsequent formation of a directionally orientedprovisional matrix. The tissue space being defined here includes, but isnot limited to, the region surrounding a site of tissue deficit ordamage, including a wound or incision.

Fluid flow into, through, or out of the tissue space can be refined anddirected through the inclusion of additional elements to the systemincluding manifolds and/or scaffolds. The coordinated elements of thesystem are designed to create flow parameters, pathways, and patternssufficiently detailed in scale as to be able to influence and direct thecontrolled adsorption of proteins, the organization of matrix, andorganized colonization of specific cell types. Individual elements ofthe system are as follows.

Source or Generator of Flow. Flow is induced into, through, or out ofthe tissue space by methods or apparatuses that introduce changes inmechanical, chemical, and/or electrical potentials. These generators offlow provide either a gradient or a change in potential from the site orreservoir of endogenous or exogenous fluids to the placement position ofthe flow generator or its extension element (i.e., manifold orscaffold). In one embodiment, the source of flow comprises a source ofreduced pressure. Systems and apparatuses according to the invention mayalso comprise valves or arrays of valves that control the applicationand amount of negative pressure applied to the manifold. In certainaspects, scaffolds and/or manifolds described herein comprise a pressuresensor. Thus, in some embodiments, the amount of negative pressureapplied by a source is regulated based on the amount of negativepressure that is sensed in the manifold or scaffold or at the site oftissue damage.

Manifold. The flow generators are the driving force for stimulating theflow of fluids. Manifolds are apparatuses for refining the pattern offlow between the source or generator of flow and the tissue space. Themacroscale level of flow is refined by specialized manifolds utilizedfor directed localization to a single point or to a plurality ofselectively positioned points for creating initiation sites formicroscale flow pathways within the manifold/scaffold and, ultimately,the tissue space. The manifold may also serve as a conduit for theremoval of fluids from and as an apparatus for the delivery of exogenousfluids to the tissue space.

A manifold generally refers to a physical substance or structure thatserves to assist in applying and translating a mechanical, chemical,electrical or similar alterations into changes in the flow of a fluid,herein defined as the movement of liquids, gases, and other deformablesubstances such as proteins, cells, and other like moieties. As such,this physical device includes a single point or plurality of points forthe egress or evacuation of pressure, fluids, and like substancescapable of translating the movement of fluids in a scaffold, as definedabove. This can include, but is not limited to, the introduction ofexogenous factors such as cells and/or therapeutic moieties into thescaffold through the lumen or plurality of lumens present in themanifold. In addition, as used herein, a manifold includes a singlepoint or plurality of points for the ingress or introduction of fluidfrom the scaffold back towards the point source of flow.

Flow distributed by the manifold can direct the movement of endogenousproteins, growth factors, cytokines, and cells from their residentlocations within the host to the tissue space or scaffold in anorganized manner. The establishment of flow along these pathways leadsto the deposition of proteins and provisional matrix that creates aninterfacial endogenous network connecting the host to the scaffold.Extensions of this matrix can be established within the scaffold throughselective positioning of the manifold flow initiation sites with flowpromoting scaffolding designs. The organized protein deposition andprovisional matrix provide a biochemical and physical framework thatstimulates the attachment and migration of cells along directed pathwaysthroughout the scaffold and the tissue space. The resulting endogenousnetwork of proteins, growth factors, and cells provides a foundationupon which subsequent phases of the body's own tissue repair andregeneration mechanisms can build.

When in place, the manifold works in conjunction with a flow generatingsource and a scaffold, if present. Flow generating sources include, butare not limited to generators of negative pressure; generators ofpositive pressure; and generators of osmotic flow. The flow gradientestablished in the manifold may be further refined through the scaffold,to deliver a flow gradient to the scaffold to optimize flow through thescaffold as needed for the particular defect. Many of the embodimentsdisclosed herein are manifolds capable of translating changes inpressure and the like into controlled movement of fluids, optionallythrough a physical scaffold, for the purposes of directed tissueregeneration. These embodiments are generally specified for a particularapplication in the regeneration of specific tissues, but are not limitedto a particular tissue therein.

In order to realize the goal of inducing flow for the purpose of tissueregeneration, alterations in the aforementioned mechanical, chemical, orelectrical impetus must be translated from the singular gradient sourcetoward a physical substrate or scaffold to elicit cellular-level changesin protein adsorption, matrix organization, cell migration, and othertissue regeneration-related behaviors. These alterations aremultivariate in nature and can include mechanical changes that elicit aphysical change in pressure applied to the scaffold as applied to thesite of the wound or desired site of tissue regeneration, chemicalchanges that elicit a gradient in protein and/or ion concentrations,which result in the creation of osmotic gradients capable of inducingflow, or electrical changes that create a gradient of current/ionexchange allowing for propagation of electrical signals from the pointsource. It is to be understood, however, that the applicants are notbound by any particular mechanism through which gradients and fluid flowinduce advantageous results in tissue repair or growth. In order toadvantageously transmit these gradients to the tissue, a physical deviceis needed to direct the path of flow from its source to the scaffold ortissue site and vice versa.

In some embodiments, the manifold comprises a physical structure inclose apposition to or within the contents of a scaffold and serves topropagate an alteration in a physical parameter, whether it bemechanical, chemical, electrical, or something similar in nature, forthe means of directing these changes from its point source to thescaffolding material. The placement of this manifold with respect to itslocation with regard to that of the scaffold may be of crucialimportance for facilitating controlled and directed regeneration ofspecific tissue types. For example, the manifold may be situated suchthat implanted tissue, such as a tissue lamina, is between the manifoldand blood source at a tissue site so that fluid from the blood source orinterstitial fluids can flow to or through the implanted tissue

Manifolds may be composed of a bioabsorbable or bioinert material.Examples include non-bioabsorbable materials such as medical gradesilicone polymers, metals, polyvinylchloride (PVC), and polyurethane(e.g., GranuFoam®), Bioabsorbable polymers such as collagen, polylacticacid (PLA), polyglycolic acid (PGA), polylactide-co-glycolide (PLGA), apolysaccharide (e.g., alginates), a hydrogel, or a polyethylene glycol,or combinations thereof, can also be used. In certain aspects, amanifold is composed of a mechanically stiff materials such as a calciumphosphate, hydroxyapatite, DBM, carbonates or bioglass. Suchmechanically stiff materials may have particular use in filling hardtissue defects. Some manifolds are also a mix of non-bioresorbable andbioresorbable materials. In general material used for a scaffold mayalso be used to compose a manifold and such materials are furtherdetailed below. In certain aspects, manifold materials are structured toinclude a high void fraction for improved bioabsorption properties. Insome embodiments, the manifold may embody characteristics of thescaffold.

Scaffold. Biologic and synthetic scaffolds are used in the field oftissue engineering to support protein adhesion and cellular ingrowth fortissue repair and regeneration. The current state of the art in scaffoldtechnology relies upon the inherent characteristics of the surroundingtissue space for the adsorption of proteins and migration of cells. Ascaffold for use according to the invention is coupled to a manifold,provides physical guidance to direct the pathway of fluid flow in thetissue site, creating avenues for the movement and migration of adhesiveproteins and cells, respectively, which are integral to theestablishment of a provisional matrix in predetermined patterns oforganization within the tissue space. The methods and apparatusesdescribed for fluid flow-induced and gradient-induced generation oftissues have direct implications into the design of the scaffolds.Within this context, scaffolds serve to refine the pathways of fluidflow within the tissue space to cellular level patterns from the fluidsource to the point(s) of flow initiation within the manifold. Ascaffold may embody characteristics of a manifold or be combined inconjunction with a manifold for refinement of the flow pathways withinthe tissue site. In certain aspects, a scaffold is a reticulatedstructure comprising high void fraction for improved bioabsorptionproperties.

Nonlimiting examples of suitable scaffold materials includeextracellular matrix proteins such as fibrin, collagen or fibronectin,and synthetic or naturally occurring polymers, including bioabsorbableor non-bioabsorbable polymers, such as polylactic acid (PLA),polyglycolic acid (PGA), polylactide-co-glycolide (PLGA),polyvinylpyrrolidone, polycaprolactone, polycarbonates, polyfumarates,caprolactones, polyamides, polysaccharides (including alginates (e.g.,calcium alginate) and chitosan), hyaluronic acid, polyhydroxybutyrate,polyhydroxyvalerate, polydioxanone, polyethylene glycols, poloxamers,polyphosphazenes, polyanhydrides, polyamino acids, polyortho esters,polyacetals, polycyanoacrylates, polyurethanes, polyacrylates,ethylene-vinyl acetate polymers and other acyl substituted celluloseacetates and derivatives thereof, polystyrenes, polyvinyl chloride,polyvinyl fluoride, poly(vinylimidazole), chlorosulphonated polyolefins,polyethylene oxide, polyvinyl alcohol, Teflon®, and nylon. The scaffoldcan also comprise ceramics such as hydroxyapatite, coralline apatite,calcium phosphate, calcium sulfate, calcium carbonate or othercarbonates, bioglass, allografts, autografts, xenografts, decellularizedtissues, or composites of any of the above. In particular embodiments,the scaffold comprises collagen, polylactic acid (PLA), polyglycolicacid (PGA), polylactide-co-glycolide (PLGA), a polyurethane, apolysaccharide, an hydroxyapatite, or a polytherylene glycol.Additionally, the scaffold can comprise combinations of any two, threeor more materials, either in separate areas of the scaffold, or combinednoncovalently, or covalently (e.g., copolymers such as a polyethyleneoxide-polypropylene glycol block copolymers, or terpolymers), orcombinations thereof. Suitable matrix materials are discussed in, forexample, Ma and Elisseeff, 2005, and Saltzman, 2004.

Bioactive Agents

In certain aspects, the apparatuses and methods according to theinvention concern bioactive agents. Bioactive agents may, in some cases,be incorporated directly onto a manifold or scaffold material (i.e., togenerate a bioactive manifold and/or scaffold). For example, agents thatfacilitate tissue growth such as collagen or fibrin may be directlyincorporated onto or into a manifold or scaffold material. Likewise, inapplications where aberrant immune response need be avoided (e.g.,tissue grafts) immune regulator agents such as rapamycin may beincorporated into manifold or scaffold structures.

In further aspects soluble bioactive agents may be introduced at a siteof tissue damage by virtue of the flow through the tissue site. Forexample, a manifold may be in fluid communication with a fluid sourceand a bioactive agent may be introduced into the fluid source andthereby into the manifold and tissue lamina.

Nonlimiting examples of useful bioactive growth factors for variousapplications are growth hormone (GH), a bone morphogenetic protein(BMP), transforming growth factor-α (TGF-α), a TGF-β, a fibroblastgrowth factor (FGF), granulocyte-colony stimulating factor (G-CSF),granulocyte/macrophage-colony stimulating factor (GM-CSF), epidermalgrowth factor (EGF), platelet derived growth factor (PDGF), insulin-likegrowth factor (IGF), vascular endothelial growth factor (VEGF),hepatocyte growth factor/scatter factor (HGF/SF), an interleukin, tumornecrosis factor-α (TNF-α) or nerve growth factor (NGF). In certainapplications, the bioactive molecule may be a molecule that directsvascularization such as VEGF.

Tissue repair and regeneration. The apparatuses and systems disclosedherein can be used for tissue repair and engineering in various contextsincluding the following.

Repair and regeneration of lost tissue. A generator of flow may becombined with manifolds and/or scaffolds to direct the regeneration oflost tissue at a site of injury or compromised function. Tissues lostfrom traumatic injury, surgery, burns, or other causes (e.g., infectionor autoimmune disease) can be led to regenerate using the methods,scaffolds, manifolds, flow sources and systems of the invention.

Retard the progression of a tissue disease state. A generator of flowmay be combined with manifolds and/or scaffolds to retard diseaseprogression of an affected tissue such as occurs, e.g., in autoimmunedisease and wasting infections such as a Staph infection.

Maintenance of tissue viability. A generator of flow may be combinedwith manifolds and/or scaffolds to maintain the viability of explantedtissues, such as adipose tissues, either for in vitro study, ex vivoscaffold or implant preparation, or in vivo transplant. A generator offlow combined with a manifold may be used to provide nutrient fluid flowto the tissue and to control waste removal from the tissue.

Expansion of tissue. A generator of flow may be combined with manifoldsand/or scaffolds to promote the expansion of existing tissues. Themethods, scaffolds, manifolds, flow sources and systems of the inventioncan be used to direct the growth of tissues where additional tissuequantity is needed or desired. Tissue expansion may be accomplishedeither in vivo or ex vivo, for example in a tissue culture environmentthat provides required nutrients to the tissue wherein the nutrients areinfused by the application of reduced pressure.

Acceleration of tissue formation or promoting new tissue formation. Agenerator of flow may be combined with manifolds and/or scaffolds toaccelerate the rate of tissue formation within a natural healingresponse. The methods, scaffolds, manifolds, flow sources and systems ofthe invention may be used to accelerate tissue growth by augmentingformation of provisional matrices, facilitating its stable positioning,and aiding in recruitment of cells to the tissue space. Likewise, theapparatuses and methods disclosed herein may be used to promote newtissue formation at a selected tissue site. Such new tissue formationmay be used to bulk (i.e., add volume and mass) a tissue site. Suchmethods may be used to rebuild tissue features that were lost to aninjury, malformed during development or to improve the externalappearance of a feature.

Stimulating the differentiation of stem cells along specific pathways. Agenerator of flow may be combined with manifolds and/or scaffolds tostimulate the differentiation of stem cells or other pluripotent cellsinto specific lineages. Application of flow using the methods,scaffolds, manifolds, flow sources and systems of the invention may beused to direct pluripotent cells into specific cell lineages needed tofoster growth in the tissue space. For example, adipose (e.g., brown orwhite adipocyte) progenitor cells may be provided as part of a tissuelamina and grown on a matrix either in vitro or at a tissue site invivo.

Introducing proteins, matrix, cells, or pharmaceuticals into the in vivoenvironment. A generator of flow may be combined with manifolds and/orscaffolds to introduce exogenous growth factors, proteins, cells, orpharmaceutical agents into the tissue space to augment tissue repair,regeneration, and/or maintenance.

Creating matrices in vitro for implantation in vivo. A generator of flowmay be combined with manifolds and/or scaffolds to facilitate formationof matrices in vitro that may subsequently be used for in vivotransplantation.

Promoting integration of transplanted tissue. A generator of flow may becombined with manifolds and/or scaffolds to promote integration oftransplanted tissue into the host environment. This can be applied toautograft, allograft, or xenograft transplants. Transplanted tissues maybe whole sections of tissue excised from surrounding tissue, orsubstantially disrupted tissues such as lipoaspirate. In suchapplications manifold material may include immune suppressing agents toreduce the chance of tissue rejection.

Directing extracellular matrix (ECM) deposition and orientation invitro. A flow generator may be combined with manifolds and/or scaffoldsto guide the directed deposition and orientation of ECM expressed bycells and tissues. The directed orientation of ECM has an impact inorganizing and directing the attachment and colonization of subsequentcell layers and tissues.

REFERENCES

U.S. Pat. No. 4,787,906

U.S. Pat. No. 6,103,255

U.S. Pat. No. 6,135,116

U.S. Pat. No. 6,365,146

U.S. Pat. No. 6,695,823

U.S. Pat. No. 6,696,575

U.S. Pat. No. 6,767,334

U.S. Pat. No. 6,814,079

U.S. Pat. No. 6,856,821

U.S. Pat. No. 6,936,037

U.S. Pat. No. 6,951,553

U.S. Pat. No. 6,994,702

U.S. Pat. No. 7,004,915

U.S. Pat. No. 7,070,584

U.S. Pat. No. 7,077,832

U.S. Pat. No. 7,108,683

U.S. Pat. No. 7,160,553

U.S. Pat. No. 7,186,244

U.S. Pat. No. 7,214,202

U.S. Pat. No. 7,279,612

U.S. Pat. No. 7,316,672

U.S. Pat. No. 7,346,945

U.S. Pat. No. 7,351,250

U.S. Pat. No. 7,384,786

U.S. Patent Publn. 2003/0225347

U.S. Patent Publn. 2005/0260189

U.S. Patent Publn. 2007/0123895

U.S. Patent Publn. 2008/0033324

U.S. Patent Publn. 2008/0208358

U.S. Provisional Patent Appln. 61/142,053

U.S. Provisional Patent Appln. 61/142,065

Anderson et al., Tissue Eng., 13:2525-38, 2007.

Brody et al., J. Biomed. Mater, Res. B: Appl. Biomater., 83:16-43, 2007.

Gemmiti et al., Tissue Eng., 12:469-79, 2006.

Lago et al., IEEE Trans. Biomed. Eng., 54:1129-37, 2007.

Ma et al., Scaffolding in Tissue Engineering, 2005.

Manwaring et al., Biomaterials, 22:3155-3168, 2001.

Manwaring et al., Biomaterials, 25:3631-3638, 2004.

Mercier et al., Biomaterials, 26:1945-1952, 2005.

Mikos et al., J. Biomed. Mater. Ref., 27:183-189, 2004.

Norman et al., Ann Biomed Eng., 34:89-b 101, 2006.

PCT Appln. WO 00/38755A2

PCT Appln. WO 00/61206A1

PCT Appln. WO 03/018098A2

PCT Appln. WO 03/092620A2

PCT Appln. WO 04/060148A2

PCT Appln. WO 04/105576A2

PCT Appln. WO 05/009488A2

PCT Appln. WO 05/033273A2

PCT Appln. WO 06/004951

PCT Appln. WO 06/127853

PCT Appln. WO 07/067685A2

PCT Appln. WO 07/092397A2

PCT Appln. WO 07/106589A2

PCT Appln. WO 07/106590A2

PCT Appln. WO 07/106591A2

PCT Appln. WO 07/106592A2

PCT Appln. WO 07/106594A2

PCT Appln. WO 07/133555A2

PCT Appln. WO 07/133556A2

PCT Appln. WO 07/143060A2

PCT Appln. WO 07/196590

PCT Appln. WO 08/013896A2

PCT Appln. WO 08/036162A2

PCT Appln. WO 08/036359A2

PCT Appln. WO 08/036361A2

PCT Appln. WO 08/042481A2

PCT Appln. WO 08/091521A2

Pfister et al., Neurosurgery, 60:137-41, 2007.

Saltzman, Tissue Engineering: Engineering Principles for the Design ofReplacement Organs and Tissues, 2004.

Sachlos et al., Cells and Mat., 5:29-40, 2003.

Segvich et al., J. Biomed. Mater. Res. B: Appl. Biomater., 84B:340-349,2008.

Shimko et al., J Biomed Mater. Res. B: Appl. Biomater., 73:315-24, 2005.

Takahashi et al., Cell, 126:663-76, 2006.

Tan et al., Bone, 41:745-751, 2007.

Tan et al., Biochem. Biophys. Res. Comm., 369:1150-1154, 2008.

Walsh et al., Tissue Eng., 11:1085-1094, 2005.

Wen et al., Handbook of Nanostructured Biomaterials and TheirApplications in Nanobiotechnology, 1-23, 2005.

All references cited in this specification are hereby incorporated byreference. The discussion of the references herein is intended merely tosummarize the assertions made by the authors and no admission is madethat any reference constitutes prior art. Applicants reserve the rightto challenge the accuracy and pertinence of the cited references.

In view of the above, it will be seen that the advantages of theinvention are achieved and other advantages attained. As various changescould be made in the above methods and compositions without departingfrom the scope of the invention, it is intended that all mattercontained in the above description and shown in the accompanyingdrawings shall be interpreted as illustrative and not in a limitingsense.

1.-14. (canceled)
 15. An apparatus for treating a wound having a cavity,the apparatus comprising: a scaffold including a scaffold lamina and atissue lamina, the scaffold lamina having edges and forming a laminatein fluid communication with the tissue lamina, the laminate being rolledinto a generally cylindrical shape having two end surfaces, the scaffoldfor positioning within the cavity of the wound and providing reducedpressure to the wound; and a manifold having a port for coupling to asource of reduced pressure and in fluid communication with the scaffoldto provide reduced pressure to the scaffold lamina and the wound. 16.The apparatus of claim 15, further comprising a drape formed ofsubstantially impermeable material to cover the scaffold and themanifold within the wound to substantially maintain the reduced pressurewithin the wound when provided by the manifold.
 17. The apparatus ofclaim 15, wherein the manifold is positioned adjacent one of the endsurfaces of the scaffold in fluid communication with one of the edges ofthe scaffold lamina.
 18. The apparatus of claim 15, wherein the laminatefurther comprises an end portion of the rolled laminate with thescaffold lamina also comprising an end portion, and wherein the manifoldis in fluid communication with the end portion of the scaffold lamina.19. The apparatus of claim 15, wherein the tissue lamina comprisesadipose tissue.
 20. The apparatus of claim 19, wherein the adiposetissue is derived from lipoaspirate.
 21. The apparatus of claim 15,wherein the tissue lamina comprises allograft, autograft or xenografttissue.
 22. The apparatus of claim 15, wherein the scaffold lamina isformed from a bioinert or bioabsorbable material.
 23. The apparatus ofclaim 15, wherein the scaffold lamina is formed from a foam or gelmaterial.
 24. The apparatus of claim 15, wherein the scaffold laminacomprises a bioactive agent selected from the group consisting of anantibiotic, an antibody and a growth factor.
 25. The apparatus of claim24, wherein the bioactive agent is a growth hormone (GH), a bonemorphogenetic protein (BMP), transforming growth factor-α (TGF-α), aTGF-β, a fibroblast growth factor (FGF), granulocyte-colony stimulatingfactor (G-CSF), granulocyte/macrophage-colony stimulating factor(GM-CSF), epidermal growth factor (EGF), platelet derived growth factor(PDGF), insulin-like growth factor (IGF), vascular endothelial growthfactor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF), aninterleukin, tumor necrosis factor-α (TNF-α) or nerve growth factor(NGF).
 26. The apparatus of claim 22, wherein the scaffold lamina iscomposed of collagen.
 27. The apparatus of claim 15, wherein themanifold is composed of a bioinert material.
 28. The apparatus of claim15, wherein the manifold is composed of a bioabsorbable material.
 29. Amethod for treating a wound having a cavity, the method comprising:positioning a scaffold lamina adjacent a tissue lamina to form alaminate in fluid communication with the tissue lamina; rolling thelaminate into a generally cylindrical shape having two end surfaces;positioning the scaffold within the cavity of the wound to providereduced pressure to the wound; and positioning a manifold in fluidcommunication with the scaffold to provide reduced pressure to thescaffold lamina and the wound.
 30. The method of claim 29, furthercomprising the step of covering the scaffold and the manifold within thewound with a substantially impermeable material to substantiallymaintain the reduced pressure within the wound when provided by themanifold.
 31. The method of claim 29, further comprising positioning themanifold adjacent one of the end surfaces of the scaffold in fluidcommunication with an edge of the scaffold lamina.
 32. The method ofclaim 29, further comprising positioning the scaffold lamina in fluidcommunication with an end portion of the scaffold lamina adjacent theend portion of the rolled laminate.
 33. The method of claim 29, whereinthe tissue lamina comprises adipose tissue.
 34. The method of claim 33,wherein the adipose tissue is derived from lipoaspirate.
 35. The methodof claim 29, wherein the tissue lamina comprises allograft, autograft orxenograft tissue.
 36. A method for bulking a tissue site, the methodcomprising: positioning a scaffold lamina adjacent a tissue lamina toform a laminate in fluid communication with the tissue lamina; rollingthe laminate into a generally cylindrical shape having two end surfaces;positioning the scaffold within the tissue site to provide reducedpressure to the tissue site; positioning a manifold in fluidcommunication with the scaffold to provide reduced pressure to thescaffold lamina and the tissue site.
 37. The method of claim 36, furthercomprising the step of covering the scaffold and the manifold within thewound with a substantially impermeable material to substantiallymaintain the reduced pressure within the tissue site when provided bythe manifold.
 38. The method of claim 36, further comprising positioningthe manifold adjacent one of the end surfaces of the scaffold in fluidcommunication with an edge of the scaffold lamina.
 39. The method ofclaim 36, further comprising positioning the scaffold lamina in fluidcommunication with an end portion of the scaffold lamina adjacent theend portion of the rolled laminate.
 40. The method of claim 36, whereinthe tissue lamina comprises adipose tissue.
 41. The method of claim 40,wherein the adipose tissue is derived from lipoaspirate.
 42. The methodof claim 36, wherein the tissue lamina comprises allograft, autograft orxenograft tissue.